1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Contraceptives – Pipeline Review, H1 2013

Contraceptives – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 103 pages

Contraceptives – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Contraceptives - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Contraceptives, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contraceptives. Contraceptives - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Contraceptives.
- A review of the Contraceptives products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Contraceptives pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Contraceptives.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Contraceptives pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Contraceptives - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 6
Global Markets Direct Report Coverage 6
Contraceptives Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Contraceptives 8
Contraceptives Therapeutics under Development by Companies 10
Contraceptives Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Contraceptives Therapeutics - Products under Development by Companies 18
Contraceptives Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Contraceptives Therapeutics Development 21
Antares Pharma, Inc. 21
Watson Pharmaceuticals, Inc. 22
Merck and Co., Inc. 23
BioSante Pharmaceuticals, Inc. 24
Teva Pharmaceutical Industries Limited 25
Bayer AG 26
Addex Pharmaceuticals 27
Ligand Pharmaceuticals Incorporated 28
Intas Pharmaceuticals Ltd. 29
HRA Pharma, SA 30
Pantarhei Bioscience BV 31
Hydra Biosciences, Inc. 32
Agile Therapeutics, Inc. 33
CG Therapeutics, Inc. 34
Adamis Pharmaceuticals Corporation 35
Lipocine Inc. 36
Contraceptives - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(nomegestrol + estradiol) - Drug Profile 43
(gestodene + ethinyl estradiol) - Drug Profile 45
(dehydroepiandrosterone + estradiol + progesterone) - Drug Profile 47
(nestorone + 17 beta-estradiol) - Drug Profile 49
HRA-081035 - Drug Profile 51
HRA-081025 - Drug Profile 52
E-4 - Drug Profile 53
Androgen Restored Contraceptive - Drug Profile 55
CatSper Program - Drug Profile 56
ulipristal acetate - Drug Profile 57
ulipristal acetate - Drug Profile 59
Nestorone - Drug Profile 61
DR-104 - Drug Profile 62
Ulipristal Acetate Vaginal Ring - Drug Profile 63
(ethinyl estradiol + levonorgestrel) - Drug Profile 64
levonorgestrel - Drug Profile 66
desogestrel + ethinyl estradiol - Drug Profile 68
tanaproget - Drug Profile 69
norethindrone - Drug Profile 70
levonorgestrel - Drug Profile 71
C-31-G - Drug Profile 72
meloxicam - Drug Profile 74
Contraceptive Patch Program - Drug Profile 75
DR-103 - Drug Profile 76
etonogestrel - Drug Profile 77
ADX-2 Program - Drug Profile 78
ulipristal acetate - Drug Profile 79
HRA-091015 - Drug Profile 80
Contraceptives Therapeutics - Drug Profile Updates 81
Contraceptives Therapeutics - Discontinued Products 92
Contraceptives Therapeutics - Dormant Products 93
Contraceptives - Product Development Milestones 94
Featured News and Press Releases 94
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 101
Disclaimer 101



List of Tables

Number of Products Under Development for Contraceptives, H1 2013 10
Products under Development for Contraceptives - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Antares Pharma, Inc., H1 2013 23
Watson Pharmaceuticals, Inc., H1 2013 24
Merck and Co., Inc., H1 2013 25
BioSante Pharmaceuticals, Inc., H1 2013 26
Teva Pharmaceutical Industries Limited, H1 2013 27
Bayer AG, H1 2013 28
Addex Pharmaceuticals, H1 2013 29
Ligand Pharmaceuticals Incorporated, H1 2013 30
Intas Pharmaceuticals Ltd., H1 2013 31
HRA Pharma, SA, H1 2013 32
Pantarhei Bioscience BV, H1 2013 33
Hydra Biosciences, Inc., H1 2013 34
Agile Therapeutics, Inc., H1 2013 35
CG Therapeutics, Inc., H1 2013 36
Adamis Pharmaceuticals Corporation, H1 2013 37
Lipocine Inc., H1 2013 38
Assessment by Monotherapy Products, H1 2013 39
Assessment by Combination Products, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 44
Contraceptives Therapeutics - Drug Profile Updates 83
Contraceptives Therapeutics - Discontinued Products 94
Contraceptives Therapeutics - Dormant Products 95



List of Figures

Number of Products under Development for Contraceptives, H1 2013 10
Products under Development for Contraceptives - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Discovery and Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 39
Assessment by Combination Products, H1 2013 40
Assessment by Route of Administration, H1 2013 41
Assessment by Stage and Route of Administration, H1 2013 42
Assessment by Molecule Type, H1 2013 43
Assessment by Stage and Molecule Type, H1 2013 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Related Market Segments :

Therapy

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.